Carcinogenesis, Vol. 21, No. 5, 915-919,
May 2000
© 2000 Oxford University Press
Molecular Epidemiology and Cancer Prevention |
(–)-Epigallocatechin gallate can prevent cisplatin-induced lung tumorigenesis in A/J mice
Second Department of Medicine,
1 Second Department of Pathology, Okayama University Medical School, 2-5-1 Shikata-cho, Okayama 700-8558 and
2 Department of Medicine, Okayama Red Cross General Hospital, Okayama 700-8607, Japan
Risks of secondary lung cancer in patients with non-small cell lung cancer and small cell lung cancer are estimated to be 1–2% and 2–10% per patient per year, respectively. Cisplatin is widely used in the treatment of lung cancer and is also known as a carcinogen in experimental animals. In this study, the effect of (–)-epigallocatechin gallate (EGCG) on cisplatin-induced lung tumors in A/J mice was investigated. Female A/J mice (4 weeks old) were divided into four groups: group 1, control without treatment; group 2, EGCG treatment (1 mg/ml in tap water); group 3, weekly cisplatin treatment (1.62 mg/kg body wt, i.p.) for 10 weeks; group 4, cisplatin plus EGCG treatment (EGCG was started 2 weeks before cisplatin treatment). Four groups of mice were killed at week 30 after treatment. Tumor incidence was 26.3% (5/19) in group 1, 30% (6/20) in group 2, 100% (19/19) in group 3 and 94.4% (17/18) in group 4. Tumor multiplicity (the number of tumors per mouse, mean ± SD) was 0.4 ± 0.8 in group 1, 0.4 ± 0.8 in group 2, 5.1 ± 2.1 in group 3 and 2.8 ± 2.3 in group 4. Tumor multiplicity was significantly reduced by adding EGCG to cisplatin-treated mice (P < 0.01). Furthermore, EGCG significantly reduced cisplatin-induced weight loss from 24.7–26.3% (cisplatin treatment) to 10.8–11.6% (cisplatin plus EGCG treatment) (P < 0.01). These findings suggest that EGCG can inhibit cisplatin-induced weight loss and lung tumorigenesis in A/J mice.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Sharma, P. Gao, and V. E. Steele The chemopreventive efficacy of inhaled oltipraz particulates in the B[a]P-induced A/J mouse lung adenoma model Carcinogenesis, August 1, 2006; 27(8): 1721 - 1727. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D Lambert, J. Hong, G.-y. Yang, J. Liao, and C. S Yang Inhibition of carcinogenesis by polyphenols: evidence from laboratory investigations Am. J. Clinical Nutrition, January 1, 2005; 81(1): 284S - 291S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Gaynor One Oncologist's View of Integrative Care: Keynote Address, Comprehensive Cancer Care Conference, April 2003 Integr Cancer Ther, March 1, 2004; 3(1): 82 - 87. [PDF]
|
|
|
|
 |
|
 Y.-P. Lu, Y.-R. Lou, Y. Lin, W. J. Shih, M.-T. Huang, C. S. Yang, and A. H. Conney Inhibitory Effects of Orally Administered Green Tea, Black Tea, and Caffeine on Skin Carcinogenesis in Mice Previously Treated with Ultraviolet B Light (High-Risk Mice): Relationship to Decreased Tissue Fat Cancer Res., July 1, 2001; 61(13): 5002 - 5009. [Abstract] [Full Text] [PDF]
|
|